Latest From DalCor Pharmaceuticals
Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL.
Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health
This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.
Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- DalCor Pharmaceuticals
- Senior Management
Robert McNeil, CEO
Michael Dixon, CFO
Donald M Black, MD, CMO
Louise Proulx, PhD, Chief Dev. Officer
- Contact Info
Phone: (514) 564-6474
Sherbrooke St. West, Ste. 408
Montreal, H3A 2R7
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.